van Kol Kim, Ebisch Renée, Beugeling Maaike, Cnossen Jeltsje, Nederend Joost, van Hamont Dennis, Coppus Sjors, Piek Jurgen, Bekkers Ruud
Department of Obstetrics and Gynecology, Catharina Cancer Institute, Catharina Hospital, 5623 EJ Eindhoven, The Netherlands.
Department of Obstetrics and Gynecology GROW, School for Oncology and Developmental Biology, Maastricht University Medical Center+, 6229 HX Maastricht, The Netherlands.
Cancers (Basel). 2023 Dec 31;16(1):198. doi: 10.3390/cancers16010198.
There is no consensus on the most reliable procedure to determine remission of cervical cancer after chemoradiotherapy (CRT). Therefore, this study aims to assess the diagnostic performance of two different imaging techniques, MRI and 18F[FDG]-PET/CT, in determining the presence of locoregional residual disease after CRT in patients with locally advanced cervical cancer.
Patients diagnosed with locally advanced cervical cancer (FIGO 2009) treated with CRT were retrospectively identified from a regional cohort. The accuracy of MRI and 18F[FDG]-PET/CT in detecting locoregional residual disease was assessed with histology as the reference standard.
The negative predictive value (NPV) and positive predictive value (PPV) for locoregional residual disease detection of MRI and 18F[FDG]-PET/CT combined were 84.2% (95% CI 73.2-92.1), and 70.4% (95% CI 51.8-85.2), respectively. The NPV and PPV of MRI alone were 80.2% (95% CI 71.2-87.5) and 47.7% (95% CI 35.8-59.7), respectively, and values of 81.1% (95% CI 72.2-88.3) and 55.8 (95% CI 42.2-68.7), respectively, were obtained for 18F[FDG]-PET/CT alone.
In this study, the reliability of MRI and 18F[FDG]-PET/CT in detecting locoregional residual disease was limited. Combining MRI and 18F[FDG]-PET/CT did not improve predictive values. Routine use of both MRI and 18F[FDG]-PET/CT in the follow-up after CRT should be avoided. MRI during follow-up is the advised imaging technique. Pathology confirmation of the presence of locoregional residual disease before performing salvage surgery is warranted.
对于确定宫颈癌放化疗(CRT)后缓解的最可靠方法尚无共识。因此,本研究旨在评估两种不同成像技术,即MRI和18F[FDG]-PET/CT,在确定局部晚期宫颈癌患者CRT后局部区域残留疾病存在情况时的诊断性能。
从一个地区队列中回顾性识别出接受CRT治疗的局部晚期宫颈癌(FIGO 2009)患者。以组织学为参考标准,评估MRI和18F[FDG]-PET/CT检测局部区域残留疾病的准确性。
MRI和18F[FDG]-PET/CT联合检测局部区域残留疾病的阴性预测值(NPV)和阳性预测值(PPV)分别为84.2%(95%CI 73.2 - 92.1)和70.4%(95%CI 51.8 - 85.2)。单独MRI的NPV和PPV分别为80.2%(95%CI 71.2 - 87.5)和47.7%(95%CI 35.8 - 59.7),单独18F[FDG]-PET/CT的相应值分别为81.1%(95%CI 72.2 - 88.3)和55.8(95%CI 42.2 - 68.7)。
在本研究中,MRI和18F[FDG]-PET/CT检测局部区域残留疾病的可靠性有限。联合使用MRI和18F[FDG]-PET/CT并未提高预测值。应避免在CRT后的随访中常规使用MRI和18F[FDG]-PET/CT。建议在随访期间使用MRI成像技术。在进行挽救性手术前,对局部区域残留疾病的存在进行病理确认是必要的。